SCHEMBL23395663

SCHEMBL23395663

Cn1cccc1-c1cc2ccc(O)cc2o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SHBG P04278 1/20 0.53
▸ PDE4D Q08499 3/20 0.51
▸ PDE4B Q07343 2/20 0.51
▸ TYR P14679 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ CALCRL Q16602 2/20 0.49
▸ HSD17B3 P37058 1/20 0.43
▸ APP P05067 1/20 0.43
▸ ALOX5 P09917 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ ALOX12 P18054 2/20 0.42
▸ PTPN1 P18031 2/20 0.42
▸ XDH P47989 1/20 0.42
▸ FLT3 P36888 1/20 0.41
▸ CHRNB2 P17787 1/20 0.41
▸ CHRNA4 P43681 1/20 0.41
▸ CYP19A1 P11511 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MEN1 O00255 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23395566 0.79 PTPN1 (0.48) APPPTPN1KDM4EMEN1GLA
SCHEMBL23395654 0.73 F2RL3 (0.33) APPPTPN1ALDH1A1F2RL3
SCHEMBL20473143 0.70 SHBG (0.79) SHBGPDE4DPDE4BTYRPTGS1
SCHEMBL9138143 0.70 SHBG (1.00) SHBGPDE4DPDE4BTYRPTGS1
Moracin M SCHEMBL29979946 0.68 PDE4D (1.00) SHBGPDE4DPDE4BTYRPTGS1
SCHEMBL6068079 0.68 ALOX5 (0.44) TYRALOX5ALOX15KDM4EMEN1
Moracin M SCHEMBL1740981 0.68 PDE4D (1.00) SHBGPDE4DPDE4BTYRPTGS1
SCHEMBL23395637 0.68 SHBG (0.43) SHBGPDE4DPDE4BTYRPTGS1
SCHEMBL20928071 0.66 SHBG (0.59) SHBGPDE4DPDE4BTYRPTGS1
SCHEMBL20473368 0.66 SHBG (0.51) SHBGPDE4DPDE4BTYRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
EP-3889135-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-08-02 — — EP disclosed
EP-3889135-A1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES Merck Patent GmbH (DE) 2021-10-06 — — EP disclosed
EP-3583092-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2021-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753387-B2 Compounds for optically active devices PDE6C, PDE6A, PDE6D SHBG 4847/4885PDE4D 98/4885PDE4B 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback